4th Aug 2014 08:54
LONDON (Alliance News) - Diagnostic tools and reagents company Avacta Group PLC Monday said its analytical business had completed developing two new variants of its protein characterisation instrument OPTIM and launched new software for the device, a move it hopes with widen the range of potential customers in the drug development market.
The two new variants to the OPTIM platform, OPTIM 375 and OPTIM 445, incorporate incremental measurement capabilities, it said.
"The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples," Chief Executive Alastair Smith said in a statement.
Avacta shares were down 5.4% at 0.885 pence Monday morning.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group